Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aileron Therapeutics Inc (NQ: ALRN )

2.576 +0.106 (+4.28%)
Streaming Delayed Price Updated: 11:42 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aileron Therapeutics Inc

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
From Aileron Therapeutics, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Aileron Therapeutics Inc. (NASDAQ: ALRN) Closes Underwritten Registered Direct Offering
Via Investor Brand Network
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering 
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering 
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Inc. (NASDAQ: ALRN) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Announces CEO Transition
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis 
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022 
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.